McMaster University Students Launch Amano Startup to Introduce $20 Custom 3D-Printed Hearing Aids

The landscape of global hearing healthcare could be on the verge of a profound transformation, driven by three ambitious students at McMaster University. Motivated by personal experiences witnessing their own family members struggle with the debilitating cost and logistical hurdles of hearing loss, Arish Shahab, Aaron Yu, and Ramin Syed have founded an innovative startup known as Amano. Their core mission is to dismantle the formidable financial barriers that have long kept essential hearing care out of reach for millions of people worldwide. At the heart of their enterprise is a groundbreaking, low-cost, over-the-counter hearing aid projected to cost a mere $20 a pair.

This dramatic reduction in cost offers an unprecedented and drastically more affordable alternative to standard prescription hearing devices, which all too frequently command prices scaling into the thousands of dollars. For millions of individuals living on fixed incomes or in under-resourced communities, the high cost of conventional hearing technology has meant enduring untreated hearing loss simply because the financial entry barrier is too high. Amano aims to change this narrative entirely by reimagining how hearing aids are designed, manufactured, and priced, proving that effective medical devices do not necessarily require exorbitant price tags to deliver meaningful health outcomes.

Unlike conventional models that rely on complex internal circuitry, batteries, microphones, and microprocessors, the Amano hearing aid features a purely mechanical design. Operating entirely without electronic components, the device amplifies sound through precise vibration, cleverly mimicking the ear’s natural physiological functions. This clever engineering choice not only drives down manufacturing costs to fractions of traditional hardware expenses but also eliminates the recurring annoyance and cost of purchasing replacement batteries. By stripping away unnecessary electronic complexity, the student founders have created a robust, highly accessible alternative that performs the vital task of sound amplification through mechanical physics alone.

Beyond affordability and mechanical innovation, the team behind Amano has dedicated significant thought to the psychological and social dimensions of wearing hearing technology. Social stigma has historically played a major role in discouraging individuals from seeking help for hearing loss, with many people feeling self-conscious about bulky, clinical-looking devices hanging conspicuously from their ears. To combat this pervasive social stigma, every single pair of Amano hearing aids is custom 3D-printed directly from a simple photograph of the user’s ear. Styled deliberately to mirror modern consumer earbuds, the device blends seamlessly into contemporary daily life, allowing users to wear their hearing assistance with confidence and discretion rather than fear of embarrassment.

Translating this ambitious vision from a conceptual prototype into a clinically viable medical product requires rigorous testing and scientific validation. Following initial performance and physical fit testing conducted on approximately 50 ears, the startup is currently moving into its next critical phase of development. Amano is actively seeking formal regulatory and institutional approval to conduct comprehensive clinical studies in partnership with St. Joseph’s Healthcare Hamilton. These forthcoming studies will represent a vital milestone for the young startup, providing the empirical data and medical oversight necessary to demonstrate the safety, reliability, and effectiveness of their mechanical design in real-world scenarios.

The urgency and relevance of Amano’s mission are underscored by the sheer scale of the global health challenge it seeks to address. According to international health estimates, an astounding 1.5 billion people worldwide currently experience some degree of hearing loss. When left unmanaged, hearing loss is far from a mere inconvenience; it can cascade into broader health complications, notably contributing to social isolation, depression, and accelerated cognitive decline as the brain struggles to process impoverished auditory signals. By expanding access to affordable auditory support, interventions like Amano have the potential to mitigate these secondary health risks on a massive, global scale.

This grassroots innovation arrives at a particularly critical regulatory juncture within Canada, where provincial health authorities are actively evaluating how to safely and effectively integrate over-the-counter hearing aid models into local healthcare frameworks. Regulatory landscapes are shifting, highlighted by British Columbia’s recent policy move approving non-prescription sales of hearing devices, while neighboring Ontario is actively conducting consultations on similar over-the-counter models. These regulatory shifts reflect a broader public health desire to modernize access and empower consumers, particularly aging populations and adults dealing with age-related hearing changes.

At the same time, healthcare advocates and audiologists strongly support expanding access for adults living with mild to moderate hearing loss, viewing low-cost alternatives as a powerful tool for public health equity. However, these same advocates consistently emphasize the parallel need for proper regulation, consumer education, and baseline hearing assessments. Ensuring that patients understand their specific auditory profiles and rule out more serious medical conditions before purchasing over-the-counter devices remains a vital priority for safeguarding patient safety and ensuring that individuals receive the precise level of care appropriate for their unique health needs. As Amano continues its journey from a university project toward formal clinical trials, the startup stands at the forefront of a growing movement to make hearing health a universally accessible right rather than a luxury.

Share:

rifanmuazin writes for Stepping Stones Center.